Skip header and navigation

Refine By

198 records – page 1 of 20.

The 4154delA mutation carriers in the BRCA1 gene share a common ancestry.

https://arctichealth.org/en/permalink/ahliterature153810
Source
Fam Cancer. 2009;8(1):1-4
Publication Type
Article
Date
2009
Author
Silvija Ozolina
Olga Sinicka
Eriks Jankevics
Inna Inashkina
Jan Lubinski
Bohdan Gorski
Jacek Gronwald
Tatyana Nasedkina
Olga Fedorova
Ludmila Lyubchenko
Laima Tihomirova
Author Affiliation
Latvian Biomedical Research and Study Centre, Ratsupites str. 1, Riga, 1067, Latvia.
Source
Fam Cancer. 2009;8(1):1-4
Date
2009
Language
English
Publication Type
Article
Keywords
Breast Neoplasms - genetics
DNA Mutational Analysis
Female
Founder Effect
Genes, BRCA1
Genetic Predisposition to Disease
Haplotypes
Humans
Latvia
Male
Microsatellite Repeats
Mutation
Pedigree
Poland
Polymerase Chain Reaction
Polymorphism, Single Nucleotide
Polymorphism, Single-Stranded Conformational
Russia
Abstract
Uncertainty exists whether the 4154delA mutation of the BRCA1 gene detected in unrelated individuals from Latvia, Poland and Russia is a founder mutation with a common ancestral origin. To trace back this problem we analysed the mutation-associated haplotype of the BRCA1 intragenic SNPs as well as intragenic and nearby STR markers in mutation carriers from the aforementioned populations. The mutation-associated SNP alleles were found to be "T-A-A-A-A-G" for six intragenic SNPs of the BRCA1 gene (IVS8-58delT, 3232A/G, 3667A/G, IVS16-68A/G, IVS16-92A/G, IVS18+66G/A, respectively). The alleles 195, 154, 210 and 181 were found to be associated with the 4154delA mutation for STR markers D17S1325, D17S855, D17S1328 and D17S1320, correspondingly. Further analysis of markers in the 4154delA mutation carriers from all three populations allows us to assert that all analysed mutation carriers share a common ancestry.
PubMed ID
19067236 View in PubMed
Less detail

Actor-network theory: a tool to support ethical analysis of commercial genetic testing.

https://arctichealth.org/en/permalink/ahliterature180338
Source
New Genet Soc. 2003 Dec;22(3):271-96
Publication Type
Article
Date
Dec-2003
Author
Bryn Williams-Jones
Janice E Graham
Author Affiliation
Centre for Family Research & Homerton College, University of Cambridge, UK.
Source
New Genet Soc. 2003 Dec;22(3):271-96
Date
Dec-2003
Language
English
Publication Type
Article
Keywords
Breast Neoplasms - genetics
Canada
Diffusion of Innovation
Female
Genes, BRCA1
Genes, BRCA2
Genetic Counseling
Genetic Research
Genetic Services - economics - ethics - trends
Genetic Testing - economics - ethics - methods
Health Services Accessibility
Humans
Industry
Internationality
Marketing
Models, organizational
Patents as Topic
Private Sector
Public Policy
Public Sector
Research Support as Topic
Sensitivity and specificity
Technology Assessment, Biomedical
Technology Transfer
Abstract
Social, ethical and policy analysis of the issues arising from gene patenting and commercial genetic testing is enhanced by the application of science and technology studies, and Actor-Network Theory (ANT) in particular. We suggest the potential for transferring ANT's flexible nature to an applied heuristic methodology for gathering empirical information and for analysing the complex networks involved in the development of genetic technologies. Three concepts are explored in this paper--actor-networks, translation, and drift--and applied to the case of Myriad Genetics and their commercial BRACAnalysis genetic susceptibility test for hereditary breast cancer. Treating this test as an active participant in socio-technical networks clarifies the extent to which it interacts with, shapes and is shaped by people, other technologies, and institutions. Such an understanding enables more sophisticated and nuanced technology assessment, academic analysis, as well as public debate about the social, ethical and policy implications of the commercialization of new genetic technologies.
PubMed ID
15115034 View in PubMed
Less detail

Allelic transcripts dosage effect in morphologically normal ovarian cells from heterozygous carriers of a BRCA1/2 French Canadian founder mutation.

https://arctichealth.org/en/permalink/ahliterature126306
Source
Cancer Prev Res (Phila). 2012 May;5(5):765-77
Publication Type
Article
Date
May-2012
Author
Diala Abd-Rabbo
Christine Abaji
Guillaume B Cardin
Abdelali Filali-Mouhim
Caroline Arous
Lise Portelance
Enrique Escobar
Sophie Cloutier
Patricia N Tonin
Diane M Provencher
Anne-Marie Mes-Masson
Christine M Maugard
Author Affiliation
Institut du cancer de Montréal/Centre de recherche du Centre hospitalier de l'Université de Montréal, Québec, Canada.
Source
Cancer Prev Res (Phila). 2012 May;5(5):765-77
Date
May-2012
Language
English
Publication Type
Article
Keywords
Adult
Aged
Alleles
Canada
Cells, Cultured
DNA Mutational Analysis
Female
Founder Effect
Gene Dosage - physiology
Genes, BRCA1 - physiology
Genes, BRCA2 - physiology
Heterozygote
Humans
Middle Aged
Mutation
Ovary - chemistry - cytology - metabolism
Penetrance
Quebec
RNA, Messenger - analysis - genetics
Validation Studies as Topic
Abstract
We hypothesized that the transcriptome of primary cultures of morphologically normal ovarian surface epithelial cells could be altered by the presence of a heterozygous BRCA1 or BRCA2 mutation. We aimed to discover early events associated with ovarian carcinogenesis, which could represent putative targets for preventive strategies of this silent killer tumor. We identified the first molecular signature associated with French Canadian BRCA1 or BRCA2 founder mutations in morphologically normal ovarian epithelial cells. We discovered that wild-type and mutated BRCA2 allelic transcripts were expressed not only in morphologically normal but also in tumor cells from BRCA2-8765delAG carriers. Further analysis of morphologically normal ovarian and tumor cells from BRCA1-4446C>T carriers lead to the same observation. Our data support the idea that one single hit in BRCA1 or BRCA2 is sufficient to alter the transcriptome of phenotypically normal ovarian epithelial cells. The highest level of BRCA2-mutated allele transcript expression was measured in cells originating from the most aggressive ovarian tumor. The penetrance of the mutation and the aggressiveness of the related tumor could depend on a dosage effect of the mutated allele transcript.
PubMed ID
22401979 View in PubMed
Less detail

Analysis of ZNF350/ZBRK1 promoter variants and breast cancer susceptibility in non-BRCA1/2 French Canadian breast cancer families.

https://arctichealth.org/en/permalink/ahliterature118982
Source
J Hum Genet. 2013 Feb;58(2):59-66
Publication Type
Article
Date
Feb-2013
Author
Karine V Plourde
Yvan Labrie
Sylvie Desjardins
Pascal Belleau
Geneviève Ouellette
Francine Durocher
Author Affiliation
Cancer Genomics Laboratory, Oncology and Molecular Endocrinology Research Centre, Centre Hospitalier Universitaire de Québec and Laval University, Québec City, QC, Canada.
Source
J Hum Genet. 2013 Feb;58(2):59-66
Date
Feb-2013
Language
English
Publication Type
Article
Keywords
Base Sequence
Breast Neoplasms - genetics
Canada
DNA Primers
Female
Genes, BRCA1
Genes, BRCA2
Genetic Predisposition to Disease
Haplotypes
Humans
Linkage Disequilibrium
Polymerase Chain Reaction
Promoter Regions, Genetic
Repressor Proteins - genetics
Abstract
ZNF350/ZBRK1 is a transcription factor, which associates with BRCA1 to co-repress GADD45A to regulate DNA damage repair, and the expression of ZNF350 is altered in different human carcinomas. In a previous study, we identified ZNF350 genomic variants potentially involved in breast cancer susceptibility in high-risk non-BRCA1/2 breast cancer individuals, which pointed toward a potential association for variants in the 5'-UTR and promoter regions. Therefore, direct sequencing was undertaken and identified 12 promoter variants, whereas haplotype analyses put in evidence four common haplotypes with a frequency>2%. However, based on their frequency observed in breast cancer and unrelated healthy individuals, these are not statistically associated with breast cancer risk. Luciferase promoter assays in two breast cancer cell lines identified two haplotypes (H11 and H12) stimulating significantly the expression of ZNF350 transcript compared with the common haplotype H8. The high expression of the H11 allele was associated with the variant c.-874A. Using MatInspector and Transcription Element Search softwares, in silico analyses predicted that the variant c.-874A created a binding site for the factors c-Myc and myogenin. This study represents the first characterization step of the ZNF350 promoter. Additional studies in larger cohorts and other populations will be needed to further evaluate whether common and/or rare ZNF350 promoter variants and haplotypes could be associated with a modest risk of breast cancer.
Notes
Comment In: J Hum Genet. 2013 Feb;58(2):5823223009
PubMed ID
23151675 View in PubMed
Less detail

Autoimmune hypothyroidism and breast cancer in the elderly.

https://arctichealth.org/en/permalink/ahliterature156313
Source
Breast Cancer Res Treat. 2009 Jun;115(3):635-41
Publication Type
Article
Date
Jun-2009
Author
Monty K Sandhu
Christine Brezden-Masley
Lorraine L Lipscombe
Branden Zagorski
Gillian L Booth
Author Affiliation
Department of Medicine, University of Toronto, Toronto, Canada.
Source
Breast Cancer Res Treat. 2009 Jun;115(3):635-41
Date
Jun-2009
Language
English
Publication Type
Article
Keywords
Aged
Autoimmune Diseases - complications
Breast Neoplasms - drug therapy - epidemiology - etiology
Canada - epidemiology
Cohort Studies
Female
Genes, BRCA1
Humans
Hypothyroidism - complications
Incidence
Lymphatic Metastasis
Prognosis
Retrospective Studies
Risk factors
Thyroxine - administration & dosage
Treatment Outcome
Abstract
To determine whether autoimmune hypothyroidism (AIHT) influences breast cancer (BRCA) incidence or all-cause survival.
Administrative data were used to identify elderly women living in Ontario, Canada with and without AIHT based on prescriptions for levothyroxine (LT4) (N = 178,186). Women were followed from April 1, 1994-March 31, 2003 for BRCA outcomes.
The incidence of BRCA was similar in LT4 users and a propensity-matched cohort of non-users (adjusted HR = 0.99; 95% CI: 0.92-1.07). All-cause mortality was significantly lower in LT4 users compared to non-users (HR 0.95; 95% CI: 0.93-0.97, P
PubMed ID
18604583 View in PubMed
Less detail

Being young, female, and BRCA positive.

https://arctichealth.org/en/permalink/ahliterature120673
Source
Am J Nurs. 2012 Oct;112(10):26-31, quiz 46, 32
Publication Type
Article
Date
Oct-2012
Author
Rebekah Hamilton
Author Affiliation
College of Nursing, Rush University, Chicago, IL, USA. rebekah_hamilton@rush.edu
Source
Am J Nurs. 2012 Oct;112(10):26-31, quiz 46, 32
Date
Oct-2012
Language
English
Publication Type
Article
Keywords
Adolescent
Adult
Breast Neoplasms - genetics
Canada
Education, Nursing, Continuing
Female
Genes, BRCA1
Genes, BRCA2
Genetic Predisposition to Disease
Humans
Ovarian Neoplasms - genetics
United States
Young Adult
Abstract
Women who carry a BRCA1 or BRCA2 gene mutation face a risk of developing breast or ovarian cancer at an earlier age than women without such a mutation. Relatively little is known about the psychosocial consequences-especially regarding marriage and childbearing-in young women who test positive for one of these mutations.
In 2006, participants were recruited from Web sites for women with breast cancer or BRCA gene mutations. Forty-four women ages 18 to 39 from 22 states and Canada who had had genetic testing and were found to carry a BRCA mutation were interviewed by phone or e-mail. A qualitative, grounded theory analysis was performed on the data, focusing on the participants' being young and having had genetic testing for the BRCA mutation. The findings reported here focus on three characteristics of the participants-whether or not they were married, had children, or had a breast cancer diagnosis-and how those characteristics were affected by the women's knowledge of their genetic risk.
Among the 13 unmarried participants, issues of when to disclose information about their genetic risk in intimate relationships were discussed. Many of the 24 participants who had children reported "staying alive" for their children as a primary goal; the childless women reported an urgency to have children. Of the 21 who had a breast cancer diagnosis, the youngest was 24 years old, and several said knowledge of their genetic risk influenced their decision to have the unaffected breast removed prophylactically.
A sense of being different and not understood was expressed in these interviews. These findings suggest that nurses should be aware of psychosocial issues, especially those surrounding marriage and childbearing, in their interactions with young women who carry a BRCA1 or BRCA2 gene mutation.
PubMed ID
22982855 View in PubMed
Less detail

"Be ready against cancer, now": direct-to-consumer advertising for genetic testing.

https://arctichealth.org/en/permalink/ahliterature165052
Source
New Genet Soc. 2006 Apr;25(1):89-107
Publication Type
Article
Date
Apr-2006
Author
Bryn William-Jones
Author Affiliation
Programmes de bioethique, Universite de Montreal, C.P. 6128, Succursale Centre-Ville, Montreal (Quebec) Canada H3C 3J7. bryn.williams-jones@umontreal.ca
Source
New Genet Soc. 2006 Apr;25(1):89-107
Date
Apr-2006
Language
English
Publication Type
Article
Keywords
Advertising as Topic - ethics - methods
Breast Neoplasms - diagnosis - genetics
Canada
Consumer Participation
Europe
Female
Genes, BRCA1
Genes, BRCA2
Genetic Services - economics
Genetic Testing - economics - ethics
Government Regulation
Humans
Industry
Internet
Mass Media
United States
Abstract
A recent addition to the debate about the benefits and harms of direct-to-consumer (DTC) advertising of medicines and pharmaceuticals is a growing critique of DTC marketing and sale of genetic tests. Academic and policy literatures exploring this issue have, however, tended to focus on the sale of genetic tests, paying rather less attention to the particular implications of advertising. The globalization of broadcast media and ever increasing access to the Internet mean that public exposure to advertising for medical technologies is a reality that national regulatory bodies will be hard pressed to constrain. Working through a case study detailing Myriad Genetics' 2002 pilot advertising campaign for their BRACAnalysis genetic susceptibility test for hereditary breast and ovarian cancer, this paper highlights some of the diverse and often overlooked and unregulated approaches to DTC advertising, and the associated social, ethical and policy implications.
PubMed ID
17312631 View in PubMed
Less detail

Bilateral prophylactic mastectomy in Swedish women at high risk of breast cancer: a national survey.

https://arctichealth.org/en/permalink/ahliterature134424
Source
Ann Surg. 2011 Jun;253(6):1147-54
Publication Type
Article
Date
Jun-2011
Author
Brita Arver
Karin Isaksson
Hans Atterhem
Annika Baan
Leif Bergkvist
Yvonne Brandberg
Hans Ehrencrona
Monica Emanuelsson
Henrik Hellborg
Karin Henriksson
Per Karlsson
Niklas Loman
Jonas Lundberg
Anita Ringberg
Marie Stenmark Askmalm
Marie Wickman
Kerstin Sandelin
Author Affiliation
Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden.
Source
Ann Surg. 2011 Jun;253(6):1147-54
Date
Jun-2011
Language
English
Publication Type
Article
Keywords
Adult
Aged
Breast Neoplasms - epidemiology - genetics - pathology - surgery
Female
Genes, BRCA1
Genes, BRCA2
Genetic Predisposition to Disease
Health Care Surveys
Humans
Incidence
Mastectomy
Middle Aged
Reoperation
Risk assessment
Risk factors
Sweden - epidemiology
Abstract
This study attempted a national inventory of all bilateral prophylactic mastectomies performed in Sweden between 1995 and 2005 in high-risk women without a previous breast malignancy. The primary aim was to investigate the breast cancer incidence after surgery. Secondary aims were to describe the preoperative risk assessment, operation techniques, complications, histopathological findings, and regional differences.
Geneticists, oncologists and surgeons performing prophylactic breast surgery were asked to identify all women eligible for inclusion in their region. The medical records were reviewed in each region and the data were analyzed centrally. The BOADICEA risk assessment model was used to calculate the number of expected/prevented breast cancers during the follow-up period.
A total of 223 women operated on in 8 hospitals were identified. During a mean follow-up of 6.6 years, no primary breast cancer was observed compared with 12 expected cases. However, 1 woman succumbed 9 years post mastectomy to widespread adenocarcinoma of uncertain origin. Median age at operation was 40 years. A total of 58% were BRCA1/2 mutation carriers. All but 3 women underwent breast reconstruction, 208 with implants and 12 with autologous tissue. Four small, unifocal, invasive cancers and 4 ductal carcinoma in situ were found in the mastectomy specimens. The incidence of nonbreast related complications was low (3%). Implant loss due to infection/necrosis occurred in 21 women (10%) but a majority received a new implant later. In total, 64% of the women underwent at least 1unanticipated secondary operation.
Bilateral prophylactic mastectomy is safe and efficacious in reducing future breast cancer in asymptomatic women at high risk. Unanticipated reoperations are common. Given the small number of patients centralization seems justified.
PubMed ID
21587115 View in PubMed
Less detail

BRCA1 1675delA and 1135insA account for one third of Norwegian familial breast-ovarian cancer and are associated with later disease onset than less frequent mutations.

https://arctichealth.org/en/permalink/ahliterature20699
Source
Dis Markers. 1999 Oct;15(1-3):79-84
Publication Type
Article
Date
Oct-1999
Author
A. Borg
A. Dørum
K. Heimdal
L. Maehle
E. Hovig
P. Møller
Author Affiliation
Department of Oncology, University Hospital, Lund, Sweden.
Source
Dis Markers. 1999 Oct;15(1-3):79-84
Date
Oct-1999
Language
English
Publication Type
Article
Keywords
Adult
Age of Onset
Breast Neoplasms - epidemiology - genetics
DNA Mutational Analysis
Female
Founder Effect
Genes, BRCA1
Genetic Predisposition to Disease
Genetic Screening
Humans
Middle Aged
Mutagenesis, Insertional
Mutation
Neoplastic Syndromes, Hereditary - epidemiology - genetics
Norway - epidemiology
Ovarian Neoplasms - epidemiology - genetics
Research Support, Non-U.S. Gov't
Sequence Deletion
Abstract
A total of 845 women from breast-ovarian cancer kindreds were enrolled in a clinical follow-up program for early disease diagnosis; 35 women were prospectively identified with cancer. In order to estimate the role of genetic factors for cancer predisposition in this well-defined set of patients, considered as representative for familial breast-ovarian cancer in the Norwegian population, the BRCA1 gene was investigated for germline mutations. The entire coding region of BRCA1 was analysed using a protein truncation test, direct sequencing and a screen for known large genomic deletions and insertions. Twenty one (60%) of the 35 patients were identified as carriers of 11 distinct BRCA1 mutations. Two previously described founder mutations, 1675delA and 1135insA, were found to account for more than half (11/21) of all BRCA1 cases and for almost one third (11/35) of all breast and ovarian cancers. Supported by a previous population-based analysis of these founder mutations in ovarian cancer, our findings suggest that a significant proportion of women at risk for developing inherited breast and ovarian cancer can be identified. This is particularly obvious in certain geographic regions where these founder mutations are prevalent. Women carrying the two founder mutations had a significantly older age of disease onset as compared to women with other BRCA1 mutations. This observation indicates that BRCA mutation penetrance estimates from populations with strong founder effects may be biased. One reason why some deleterious mutations are allowed to prevail in a population may be coupled to penetrance and the fact that they seldom induce disease in women in child-bearing ages. Eleven out of 12 (92%) breast cancers in BRCA1 mutation carriers were estrogen receptor negative, versus 4 out of 9 (44%) in mutation negative patients (p = 0.03). Histopathological characteristics of the prospectively detected cancers indicated an unfavourable prognosis in mutation carriers.
PubMed ID
10595257 View in PubMed
Less detail

BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families.

https://arctichealth.org/en/permalink/ahliterature171141
Source
Breast Cancer Res. 2006;8(1):R3
Publication Type
Article
Date
2006
Author
Antonis C Antoniou
Francine Durocher
Paula Smith
Jacques Simard
Douglas F Easton
Author Affiliation
Cancer Research UK Genetic Epidemiology Unit, Strangeways Research Laboratory, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK. antonis@srl.cam.ac.uk
Source
Breast Cancer Res. 2006;8(1):R3
Date
2006
Language
English
Publication Type
Article
Keywords
Adolescent
Adult
Aged
Breast Neoplasms - epidemiology - etiology - genetics
Canada - epidemiology
DNA Mutational Analysis
Female
France - ethnology
Genes, BRCA1
Genes, BRCA2
Genetic Counseling
Genetic Predisposition to Disease
Humans
Middle Aged
Models, Theoretical
Ovarian Neoplasms - epidemiology - etiology - genetics
Pedigree
Predictive value of tests
Risk assessment
Sensitivity and specificity
Abstract
Several genetic risk models for breast and ovarian cancer have been developed, but their applicability to specific populations has not been evaluated. We used data from French-Canadian families to evaluate the mutation predictions given by the BRCAPRO and BOADICEA models. We also used this data set to estimate the age-specific risks for breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers.
A total of 195 families with multiple affected individuals with breast or ovarian cancer were recruited through the INHERIT (INterdisciplinary HEalth Research International Team on BReast CAncer susceptibility) BRCAs research program. Observed BRCA1 and BRCA2 mutation status was compared with predicted carrier probabilities under the BOADICEA and BRCAPRO models. The models were assessed using Brier scores, attributes diagrams and receiver operating characteristic curves. Log relative risks for breast and ovarian cancer in mutation carriers versus population risks were estimated by maximum likelihood, using a modified segregation analysis implemented in the computer program MENDEL. Twenty-five families were eligible for inclusion in the BRCA1 penetrance analysis and 27 families were eligible for the BRCA2 penetrance analysis.
The BOADICEA model predicted accurately the number of BRCA1 and BRCA2 mutations for the various groups of families, and was found to discriminate well at the individual level between carriers and noncarriers. BRCAPRO over-predicted the number of mutations in almost all groups of families, in particular the number of BRCA1 mutations. It significantly overestimated the carrier frequency for high predicted probabilities. However, it discriminated well between carriers and noncarriers. Receiver operating characteristic (ROC) curves indicate similar sensitivity and specificity for BRCAPRO and BOADICEA. The estimated risks for breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers were consistent with previously published estimates.
The BOADICEA model predicts accurately the carrier probabilities in French-Canadian families and may be used for counselling in this population. None of the penetrance estimates was significantly different from previous estimates, suggesting that previous estimates may be appropriate for counselling in this population.
Notes
Cites: Br J Cancer. 2000 Nov;83(10):1301-811044354
Cites: Am J Hum Genet. 1998 Mar;62(3):676-899497246
Cites: Am J Hum Genet. 2001 Mar;68(3):700-1011179017
Cites: Cancer Epidemiol Biomarkers Prev. 2001 May;10(5):467-7311352856
Cites: Clin Genet. 2001 Jun;59(6):418-2311453973
Cites: Annu Rev Genomics Hum Genet. 2001;2:69-10111701644
Cites: J Clin Oncol. 2002 Mar 15;20(6):1480-9011896095
Cites: Cancer Epidemiol Biomarkers Prev. 2002 Apr;11(4):329-3611927492
Cites: J Clin Oncol. 2002 Jun 1;20(11):2701-1212039933
Cites: Lancet. 1998 Oct 24;352(9137):1337-99802270
Cites: J Natl Cancer Inst. 1999 Jun 2;91(11):943-910359546
Cites: J Natl Cancer Inst. 1999 Jul 21;91(14):1241-710413426
Cites: Clin Genet. 1999 May;55(5):318-2410422801
Cites: J Natl Cancer Inst. 1999 Aug 4;91(15):1310-610433620
Cites: Cancer Epidemiol Biomarkers Prev. 1999 Sep;8(9):741-710498392
Cites: Hum Genet. 2005 Jul;117(2-3):119-3215883839
Cites: J Med Genet. 2005 Jul;42(7):602-315994883
Cites: J Med Genet. 2005 Sep;42(9):711-916141007
Cites: Clin Cancer Res. 2002 Dec;8(12):3776-8112473589
Cites: Lancet. 2003 Mar 29;361(9363):1101-212672316
Cites: Am J Hum Genet. 2003 May;72(5):1117-3012677558
Cites: Science. 2003 Oct 24;302(5645):643-614576434
Cites: Breast Cancer Res. 2003;5(6):R206-1614580256
Cites: Stat Med. 2004 Apr 15;23(7):1111-3015057881
Cites: J Med Genet. 2004 Jun;41(6):474-8015173236
Cites: Int J Cancer. 2004 Nov 10;112(3):411-915382066
Cites: Br J Cancer. 2004 Oct 18;91(8):1580-9015381934
Cites: Clin Genet. 1977 Oct;12(4):208-12334399
Cites: Stat Med. 1986 Sep-Oct;5(5):421-333786996
Cites: Nucleic Acids Res. 1987 Nov 25;15(22):96113684611
Cites: Genet Epidemiol. 1988;5(6):471-23061869
Cites: Cancer. 1994 Feb 1;73(3):643-518299086
Cites: Am J Hum Genet. 1995 Jan;56(1):254-647825586
Cites: Am J Hum Genet. 1995 Jan;56(1):265-717825587
Cites: Nat Genet. 1995 Oct;11(2):198-2007550349
Cites: Nat Genet. 1996 May;13(1):117-98673089
Cites: Nat Genet. 1996 May;13(1):126-88673092
Cites: J Natl Cancer Inst. 1997 Feb 5;89(3):227-389017003
Cites: N Engl J Med. 1997 May 15;336(20):1401-89145676
Cites: N Engl J Med. 1997 May 15;336(20):1409-159145677
Cites: Am J Hum Genet. 1998 Jan;62(1):145-589443863
Cites: Am J Hum Genet. 2001 Feb;68(2):410-911170890
PubMed ID
16417652 View in PubMed
Less detail

198 records – page 1 of 20.